Literature DB >> 2351143

Synergism between cefotaxime and fosfomycin in the therapy of methicillin and gentamicin resistant Staphylococcus aureus infection in rabbits.

P Chavanet1, E Muggeo, A Waldner, S Dijoux, D Caillot, H Portier.   

Abstract

An experimental model of infected subcutaneous fibrin clots in rabbits was used to study the synergism between cefotaxime and fosfomycin in infection with methicillin and gentamicin resistant Staphylococcus aureus (MGRSA), and to determine the efficacy of a simplified schedule of administration. The bactericidal activity of cefotaxime and fosfomycin against MGRSA was investigated giving the drugs in one full or two divided doses either alone or in combination. The pharmacokinetics of the drugs were correlated with the antibacterial efficacy obtained over 12 hours of treatment. The results confirmed that the combination of cefotaxime and fosfomycin is highly synergistic in experimental MGRSA infection. Higher bactericidal activity was obtained with a regimen of 6-hourly drug administration which resulted in persistent levels of both drugs in serum as well as at the site of infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351143     DOI: 10.1007/bf01968058

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

Review 1.  Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins.

Authors:  L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 2.  Methicillin-resistant Staphylococcus aureus.

Authors:  W Brumfitt; J Hamilton-Miller
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

3.  World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

4.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

5.  Outbreak of hospital infection with a strain of Staphylococcus aureus resistant to gentamicin and methicillin.

Authors:  D C Shanson; J C Kensit; R Duke
Journal:  Lancet       Date:  1976-12-18       Impact factor: 79.321

6.  In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus.

Authors:  S Alvarez; M Jones; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  Bactericidal activity of cefotaxime and fosfomycin in cerebrospinal fluid during the treatment of rabbit meningitis experimentally induced by methicillin-resistant Staphylococcus aureus.

Authors:  A Kazmierczak; A Pechinot; J C Tremeaux; J M Duez; E Kohli; H Portier
Journal:  Infection       Date:  1985       Impact factor: 3.553

8.  Antimicrobial chemotherapy of septicemia due to methicillin-resistant Staphylococcus aureus.

Authors:  M T Cafferkey; R Hone; C T Keane
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

9.  [Combination between fosfomycin and oxacillin or cefotaxime against methicillin-resistant Staphylococci and Enterococci].

Authors:  J M Duez; E Kohli; A Pechinot; J C Tremeaux; A Kazmierczak
Journal:  Pathol Biol (Paris)       Date:  1983-06

10.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.

Authors:  B F Farber; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

View more
  3 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin.

Authors:  M E Pachón-Ibáñez; S Ribes; M A Domínguez; R Fernández; F Tubau; J Ariza; F Gudiol; C Cabellos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-16       Impact factor: 3.267

3.  Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

Authors:  A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.